Contents

August 2012 • Volume 6 Number 3

3 Editorial comment
Tracy Crooks

4 The new pharmacovigilance legislation
Questions & Answers provided by the EMA relating to what is undoubtedly the biggest change to the EU regulation of medicines for over 17 years.

10 Lost in translation?
When patient information crosses borders
The Danish authors look at the possible misunderstandings and safety risks of translating PILs into various languages
Inger Askehave and Karen Kornning Zethsen

14 The use of safety biomarkers for risk assessment of investigative drugs entering first time in human studies
Sensitive biomarkers are increasingly important in identifying early toxicity and so improving the selection of drugs with therapeutic potential.
Nicholas APS Buss

17 The role of the contract QPPV
The challenges faced by the contract QPPV and the MAH when overseeing vigilance activities
Deidre McCarthy

20 UK Inspection findings for 2011/2012
Recently published figures show a continuing improvement in compliance, quality data and product safety concerns